Hosted on MSN6d
FDA approves 'ketamine' nasal spray for depression — here's everything you need to know
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
GlobalData on MSN1d
USPTO grants patent to Vistagen’s neuropathic pain treatment
The US Patent and Trademark Office (USPTO) has granted a patent to Vistagen’s non-opioid oral product candidate, AV-101 for ...
Imagine Healthcare Announces Expanded Access To Spravato - Now Available Without The Need For An Oral Antidepressant
( MENAFN - EIN Presswire) Spravato® (esketamine) has been approved for use as a standalone treatment for depression, without the requirement of an accompanying antidepressant. Legal Disclaimer: ...
stocknews2d
3 Dividend Aristocrats With Consistent Payouts
Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like ...
Medscape4d
Efficacy, Safety and Tolerability of Escitalopram in Doses up to 50 mg in Major Depressive Disorder (MDD)
There is limited published data at higher doses and none in the treatment of Major Depressive Disorder (MDD). Methods This open-label, pilot study was designed to investigate the efficacy ...
Frontiers4d
Gender Differences in Dysfunctional Attitudes in Major Depressive Disorder
Gender also plays an important role in many clinical features of major depressive disorder (MDD). This study is aimed at investigating the gender differences in dysfunctional attitudes in patients ...